1.Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S: Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63:651–657
2.Small GW: Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer’s disease. Adv Drug Deliv Rev 2002; 54:1561–1566
3.Mayeux R: Epidemiology of neurodegeneration. Ann Rev Neurosci 2003; 26:81–104
4.Baxter LC, Caselli RJ, Johnson SC, Reiman EM, Osborne D: Apolipoprotein E ε affects new learning in cognitively normal individuals at risk for Alzheimer’s disease. Neurobiol Aging 2003; 24:947–952
5.Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, Alexander GG: Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE ε allele. Neurology 2004; 62:1990–1995
6.Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D: Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334:752–758
7.Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J: Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci USA 2004; 101:284–289
8.Burggren AC, Small GW, Sabb FW, Bookheimer SY: Specificity of brain activation patterns in people at genetic risk for Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:44–51
9.Petrella J, Lustig C, Bucher L, Jha A, Doraiswamy P: Prefrontal activation patterns in subjects at risk for Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:112–113
10.Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW: Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med 2000; 343:450–456
11.Smith CD, Andersen AH, Kryscio RJ, Schmitt FA, Kindy MS, Blonder LX, Avison MJ: Altered brain activation in cognitively intact individuals at high risk for Alzheimer’s disease. Neurology 1999; 53:1391–1396
12.Smith CD, Andersen AH, Kryscio RJ, Schmitt FA, Kindy MS, Blonder LX, Avison MJ: Women at risk for AD show increased parietal activation during a fluency task. Neurology 2002; 58:1197–1202
13.Bondi MW, Houston WS, Eyler LT, Brown GG: fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer’s disease. Neurology 2005; 64:501–508
14.Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, Santulli RB: Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004; 127:1574–1583
15.Kensinger EA, Shearer DK, Locascio JJ, Growdon JH, Corkin S: Working memory in mild Alzheimer’s disease and early Parkinson’s disease. Neuropsychology 2003; 17:230–239
16.Rosen VM, Bergeson JL, Putnam K, Harwell A, Sunderland T: Working memory and apolipoprotein E: what’s the connection? Neuropsychologia 2002; 40:2226–2233
17.Delis DC, Kramer JH, Kaplan E, Ober BA: California Verbal Learning Test: Adult Version Research Edition Manual. San Antonio, Psychological Corporation, 1987
18.Delis DC, Kramer JH, Kaplan E, Ober BA: California Verbal Learning Test-2nd ed: Adult Version Manual. San Antonio, Psychological Corporation, 2000
19.Wechsler D: Wechsler Memory Scale, 3rd ed: WMS-III Administration and Scoring Manual. San Antonio, Tex., Psychological Corporation, 1997
20.Spreen O, Strauss E: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. New York, Oxford University Press, 1998
21.Delis D, Kaplan E: Delis-Kaplan Executive Function System. San Antonio, Texas, Psychological Corporation, 2001
22.Goodglass H, Kaplan E, Barresi B: Boston Diagnostic Aphasia Examination, 3rd ed. Philadelphia, Lippincott Williams & Wilkins, 2001
23.Yesavage JA, Brink TL, Lose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of geriatric depression rating scale: a preliminary report. J Psychiatr Res 1982; 17:37–49
24.Squire LR: ECT and memory loss. Am J Psychiatry 1977; 134:997–1001
25.Barona A, Reynolds C, Chastain R: A demographically based index of pre-morbid intelligence for the WAIS-R. J Consult Clin Psychol 1984; 52:885–887
26.Jonides J, Schumacher EH, Smith EE, Lauber E, Awh E, Minoshima S, Koeppe RA: The task load of verbal working memory affects regional brain activation as measured by PET. J Cogn Neurosci 1997; 9:462–475
27.McAllister TW, Saykin AJ, Flashman LA, Sparling MB, Johnson SC, Guerin SJ, Mamourian A, Weaver J, Yanofsky N: Brain activation during working memory 1 month after mild traumatic brain injury: a functional MRI study. Neurology 1999; 53:1300–1308
28.Wishart HA, Saykin AJ, McDonald BC, Mamourian AC, Flashman LA, Schuschu KR, Ryan KA, Fadul CE, Kasper LH: Brain activation patterns associated with working memory in relapsing-remitting MS. Neurology 2004; 62:234–238
29.Reymer W, Groenemeyer V, Van De Burg R, Kastelin J: Apolipoprotein E genotyping on agarose gels. Clin Chem 1995; 41:1046–1047
30.Koch W, Ehrenhaft A, Greisser K, Pfeufer A, Muller J, Schomig A, Kastrati A: Taqman systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin Chem Lab Med 2002; 40:1123–1131
31.Parasuraman R, Greenwood PM, Sunderland T: The apolipoprotein E gene, attention, and brain function. Neuropsychology 2002; 16:254–274
32.Smith JD: Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev 2002; 1:345–365
33.Nathoo N, Chetty R, van Dellen JR, Barnett GH: Genetic vulnerability following traumatic brain injury: the role of apolipoprotein E. Mol Pathol 2003; 56:132–136
34.Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M, Michaelson DM, Korczyn AD: APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 56:312–316
35.Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, Mott LA: The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003; 12:612–619
36.Laskowitz DT, Horsburgh K, Roses AD: Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 1998; 18:465–471
37.Lahiri DK, Sambamurti K, Bennett DA: Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer’s disease. Neurobiol Aging 2004; 25:651–660
38.Laws SM, Hone E, Gandy S, Martins RN: Expanding the association between the APOE gene and the risk of Alzheimer’s disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003; 84:1215–1236
39.Kato T, Knopman D, Liu H: Dissociation of regional activation in mild AD during visual encoding: a functional MRI study. Neurology 2001; 57:812–816
40.Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O’Brien PC, Petersen RC, Boeve BF, Knopman D, Tang-Wai DF, Ivnik RJ, Smith GE, Tangalos EG, Jack CR, Jr: Comparison of memory fMRI response among normal, MCI, and Alzheimer’s patients. Neurology 2003; 61:500–506
41.Rombouts SA, Barkhof F, Hoogenraad FG, Sprenger M, Scheltens P: Within-subject reproducibility of visual activation patterns with functional magnetic resonance imaging using multislice echo planar imaging. Magn Reson Imaging 1998; 16:105–113
42.Sperling RA, Bates JF, Chua EF, Cocchiarella AJ, Rentz DM, Rosen BR, Schacter DL, Albert M: fMRI studies of associative encoding in young and elderly controls and mild Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003; 74:44–50